Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Jiaoti Huang, Yinglu Zhou et al.|Science Translational Medicine|2019Cited by 138
Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancerWilliam Butler, Jiaoti Huang, Lingfan Xu et al.|The Journal of Pathology|2023Cited by 19
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestryBrendon M. Patierno, Jennifer A. Freedman, Wen-Chi Foo et al.|Prostate Cancer and Prostatic Diseases|2021Cited by 4